Anxiety in adults with asthma during the coronavirus disease 2019 pandemic: a Canadian perspective.

Sophia Linton, Kayley Xu, Lubnaa Hossenbaccus, Hannah Botting, Sarah Garvey, Adam Sunavsky, Lisa M Steacy, Dean A Tripp, Anne K Ellis
{"title":"Anxiety in adults with asthma during the coronavirus disease 2019 pandemic: a Canadian perspective.","authors":"Sophia Linton, Kayley Xu, Lubnaa Hossenbaccus, Hannah Botting, Sarah Garvey, Adam Sunavsky, Lisa M Steacy, Dean A Tripp, Anne K Ellis","doi":"10.1186/s13223-023-00833-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Asthma is a chronic airway inflammatory disease that affects millions of Canadians and often contributes to higher levels of anxiety among patients. Since the coronavirus disease 2019 (COVID-19) pandemic was a time of increased anxiety and fear among the Canadian population, it was thought that those with asthma may experience heightened anxiety levels due to uncertain access to care, the potential to misinterpret asthma symptoms for symptoms of COVID-19 (or vice versa), and the concern about being treated differently by those around them when experiencing asthma symptoms. Therefore, this study sought to perform a cross-sectional analysis of the asthma-anxiety relationship in adults with and without asthma in the unique context of the COVID-19 pandemic from a Canadian perspective.</p><p><strong>Methods: </strong>This study employed the COVID-19 Associated Anxiety in Allergic Rhinitis and Asthma patients Experiencing Symptoms (CAAARES) survey, consisting of COVID-19-specific questions, the Generalized Anxiety Disorder Assessment-7 (GAD-7) and the Asthma Control Questionnaire-6 (ACQ-6). Data collection occurred through the Qualtrics XM platform and data analyses were conducted with the IBM SPSS Statistics 28 software.</p><p><strong>Results: </strong>A total of 741 valid responses were collected (asthma group, n = 244; control group, n = 497). 31.6% and 26.2% of respondents in the asthma and control groups, respectively, met the diagnostic criteria for GAD. There was no significant difference (p = .067) in mean GAD-7 scores between the two groups. A Hierarchal Multiple Regression (HMR) model was developed, and neither asthma status nor ACQ-6 score had a significant predictive effect on the GAD-7 score. There was a statistically significant (p < .001) weak positive correlation (r = .22) between GAD-7 and ACQ-6 scores. In a simple mediation (SMM) model, perceived COVID-19 stress of others was not identified as a significant mediator of the relationship between ACQ-6 and GAD-7 (indirect effect β = 0.014).</p><p><strong>Conclusion: </strong>Our study of a Canadian cohort demonstrates elevated levels of anxiety overall, amongst both asthma and control groups. While AR status was significantly greater in the asthma group, it was not a significant predictive variable of GAD-7 score. Our data suggests that COVID-19-specific factors appear to have a greater contribution to anxiety than asthma status or control.</p>","PeriodicalId":7702,"journal":{"name":"Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology","volume":"19 1","pages":"73"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463471/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13223-023-00833-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Asthma is a chronic airway inflammatory disease that affects millions of Canadians and often contributes to higher levels of anxiety among patients. Since the coronavirus disease 2019 (COVID-19) pandemic was a time of increased anxiety and fear among the Canadian population, it was thought that those with asthma may experience heightened anxiety levels due to uncertain access to care, the potential to misinterpret asthma symptoms for symptoms of COVID-19 (or vice versa), and the concern about being treated differently by those around them when experiencing asthma symptoms. Therefore, this study sought to perform a cross-sectional analysis of the asthma-anxiety relationship in adults with and without asthma in the unique context of the COVID-19 pandemic from a Canadian perspective.

Methods: This study employed the COVID-19 Associated Anxiety in Allergic Rhinitis and Asthma patients Experiencing Symptoms (CAAARES) survey, consisting of COVID-19-specific questions, the Generalized Anxiety Disorder Assessment-7 (GAD-7) and the Asthma Control Questionnaire-6 (ACQ-6). Data collection occurred through the Qualtrics XM platform and data analyses were conducted with the IBM SPSS Statistics 28 software.

Results: A total of 741 valid responses were collected (asthma group, n = 244; control group, n = 497). 31.6% and 26.2% of respondents in the asthma and control groups, respectively, met the diagnostic criteria for GAD. There was no significant difference (p = .067) in mean GAD-7 scores between the two groups. A Hierarchal Multiple Regression (HMR) model was developed, and neither asthma status nor ACQ-6 score had a significant predictive effect on the GAD-7 score. There was a statistically significant (p < .001) weak positive correlation (r = .22) between GAD-7 and ACQ-6 scores. In a simple mediation (SMM) model, perceived COVID-19 stress of others was not identified as a significant mediator of the relationship between ACQ-6 and GAD-7 (indirect effect β = 0.014).

Conclusion: Our study of a Canadian cohort demonstrates elevated levels of anxiety overall, amongst both asthma and control groups. While AR status was significantly greater in the asthma group, it was not a significant predictive variable of GAD-7 score. Our data suggests that COVID-19-specific factors appear to have a greater contribution to anxiety than asthma status or control.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2019年冠状病毒病大流行期间哮喘成人的焦虑:加拿大的视角
背景:哮喘是一种慢性气道炎症性疾病,影响着数百万加拿大人,通常会导致患者更高水平的焦虑。由于2019年冠状病毒病(COVID-19)大流行是加拿大人口焦虑和恐惧加剧的时期,人们认为哮喘患者的焦虑水平可能会升高,原因是不确定是否能获得护理,可能将哮喘症状误解为COVID-19症状(反之亦然),以及担心在出现哮喘症状时被周围的人区别对待。因此,本研究试图从加拿大的角度,在COVID-19大流行的独特背景下,对患有和不患有哮喘的成年人的哮喘-焦虑关系进行横断面分析。方法:本研究采用《变应性鼻炎和有症状哮喘患者的COVID-19相关焦虑(CAAARES)调查》,包括COVID-19特异性问题、广泛性焦虑障碍评估-7 (GAD-7)和哮喘控制问卷-6 (ACQ-6)。通过Qualtrics XM平台收集数据,使用IBM SPSS Statistics 28软件进行数据分析。结果:共收集有效问卷741份(哮喘组,n = 244份;对照组,n = 497)。哮喘组和对照组分别有31.6%和26.2%的应答者符合广泛性焦虑症的诊断标准。两组患者GAD-7平均评分差异无统计学意义(p = 0.067)。建立了层次多元回归(HMR)模型,哮喘状态和ACQ-6评分对GAD-7评分均无显著预测作用。结论:我们对加拿大队列的研究表明,在哮喘组和对照组中,焦虑水平总体上都有所升高。虽然哮喘组的AR状态明显更高,但它不是GAD-7评分的显著预测变量。我们的数据表明,covid -19特异性因素似乎比哮喘状态或控制对焦虑的贡献更大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Immunoglobulin utilization in Canada: a comparative analysis of provincial guidelines and a scoping review of the literature. Mental health problems associated with idiopathic anaphylaxis. Validity of fractional exhaled nitric oxide and small airway lung function measured by IOS in the diagnosis of cough variant asthma in preschool children with chronic cough. Treatment of idiopathic anaphylaxis with dupilumab: a case report. PRevalence of the Eosinophilic Phenotype Among SeveRE asthma patients in Lebanon: results of the PREPARE study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1